Hello @Rufous McKinney.....Interesting and I'll pass this info along to my daughters as two of my grandchildren are at this particular age. Thinking about it, neither of my two (ages 50 & 47) never had EBV, which I consider to be a minor miracle, especially in the college years.
So many choices to make....Yours (& thanks)....Lenora.
Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site
Masaru Kanekiyo, Wei Bu, [...], and Gary J. Nabel
from the abstract-
By focusing presentation of the CR2-binding domain on nanoparticles, potent neutralizing antibodies were elicited in mice and non-human primates. The structurally designed nanoparticle vaccine increased neutralization 10- to 100-fold compared to soluble gp350 by targeting a functionally conserved site of vulnerability, improving vaccine-induced protection in a mouse model. This rational approach to EBV vaccine design elicited potent neutralizing antibody responses by arrayed presentation of a conserved viral entry domain, a strategy that can be applied to other viruses.